BRIEF

on I-CERAM (EPA:ALICR)

Pilot Study on Antibiotic-Loaded Ceramic Implant Launched

Stock price chart of I-CERAM (EPA:ALICR) showing fluctuations.

I.CERAM, a company specializing in biocompatible ceramic implants, has initiated a pilot clinical study in partnership with Pitié-Salpêtrière Hospital in Paris. This study aims to evaluate an antibiotic-loaded Porous Ceramic Sternal Stabilisation Implant, under the supervision of Professor Pascal Leprince, Head of the Cardiac Surgery Department.

The innovative implant, part of the S 2OP2CI project, is designed to stabilize the chest wall post-surgery and prevent bacterial contamination, which can complicate recovery. This pilot study involves ten implantations to assess the benefits of this technology. Mediastinitis, a postoperative complication, remains a serious concern and this study may contribute significantly to reducing associated risks.

Professor Leprince aims to address critical postoperative challenges through this study, which aligns with his department's reputation for excellence in cardiac surgery.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all I-CERAM news